Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

Quest Diagnostics (DGX) launched a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer’s ...

The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...

Quest Diagnostics is Thursday's IBD Stock Of The Day. Shares are lingering in a buy zone, helped by a Texas court's ruling.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...